Publications (163) Publications de JAIME CALVO ALEN

2024

  1. Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))

    Autoimmunity Reviews

  2. Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study

    Lupus

  3. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Coronavirus Disease 2019 in Rheumatic Patientswith Inflammatory Disorders: A Descriptive Study from a High Infection Incidence Region of Northern Spain

    EUROPEAN JOURNAL OF RHEUMATOLOGY, Vol. 10, Núm. 4

  3. Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel

    Autoimmunity Reviews, Vol. 22, Núm. 12

  4. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study

    Reumatologia Clinica, Vol. 19, Núm. 6, pp. 312-318

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  3. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 18, Núm. 1, pp. 33-41

  4. Impact of rheumatoid arthritis on sexuality: adaptation and validation of the Qualisex questionnaire for use in Spain

    Rheumatology International, Vol. 42, Núm. 10, pp. 1819-1829

  5. Local adaptation of recommendation-based materials for shared decision-making and management of comorbidity in rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 975-979

  6. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 988-992

  7. TNF Inhibitors Exert a “Hidden” Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients

    Biologics: Targets and Therapy, Vol. 16, pp. 187-197

2021

  1. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  2. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  3. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  4. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  5. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803

  6. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336